Amplion’s Machine Learning Platform Accelerates Precision Medicine Collaboration Dx:Revenue™ solution rapidly identifies and qualifies drug and test developer partnership opportunities Effective partnerships between pharmaceutical companies, biotechs, academia, diagnostic companies, CROs and other players along the drug development continuum are vital to achieving the realization of precision medicine For diagnostic and test providers in…(Read More)
Seattle’s annual GeekWire Summit brings together thousands of tech and business leaders for a conversation about the future. This year, organizers are hosting a panel discussion on The Quest for Personalized Medicine that will include Dr. Amanda Enstrom, Amplion’s Chief Product Officer. The October 8 discussion panel will feature industry leaders sharing recent…(Read More)
Biomarker Intelligence company to aggressively accelerate sales, marketing and execution of product roadmap Amplion, an Oregon-based Biomarker Intelligence company, announced the successful close of its Series A financing led by Greycroft with participation from existing investors, including Revolution’s Rise of the Rest Seed Fund and Imagen Capital Partners. The funds will help the…(Read More)
Recent research on clinical trial success rates that caught our eye: We are especially encouraged to see a group from MIT carrying forward the torch of drug likelihood-of-approval (LOA) analysis. That group of researchers put together this great analysis of what they call Probability of Success (POS) of clinical trials. The concept is…(Read More)
We have been working with Bio-Rad. As most of you know Bio-Rad provides the healthcare industry with innovative and useful products that help life science researchers accelerate the discovery process and medical diagnostic labs obtain faster, better results. They are one of the largest RUO and diagnostic providers in the world. Our partnership…(Read More)
We announced our new literature-focused features in our last blog post. One of the unique features of our approach is that we use deep learning concepts, a subset of machine learning, to text mine literature. A characteristic of deep learning is that various characteristics, or attributes, of a paper can be extracted. One of…(Read More)
We are excited to announce improvements to BiomarkerBase, increasing the coverage and analysis of literature. We’ve added biomarkers sourced only from literature, representing biomarkers in an earlier stage of development. With this addition there are two main benefits: Access to biomarker and supporting information that is in an early stage of development (3x more…(Read More)
When building a company, especially a startup, you look forward to moments that change your trajectory. So, when Mary Meeker included our analysis in her annual Internet trends presentation, it got us thinking. For those of you that don’t know, Mary Meeker is a venture capitalist from the influential Silicon Valley VC, Kleiner Perkins…(Read More)
What is this saying “Fail Early, Fail Fast” all about? Is there any merit to it and how is this changing the game for all pharmaceutical drug development companies? Here we will give our thoughts and opinions into how this really carries over to the real world and how it affects the industry. While no…(Read More)
As we ramp for a great 2017 we are looking back on what we did in 2016. As we ramp for a great 2017 we are looking back on what we did in 2016. In that spirit, here are the top 5 blog posts of 2016 by views. FDA Introduces a New Test Concept: “Complementary…(Read More)